Chapter 6. Management of Elevated Triglycerides and Non-High-Density Lipoprotein Cholesterol

  1. Peter P. Toth M.D., PH.D. Director of Preventive Cardiology Chief of Medicine Clinical Associate Professor1,2,3,4 and
  2. Kevin C. Maki PH.D. President Chief Science Officer5

Published Online: 1 OCT 2008

DOI: 10.1002/9780470696873.ch6

Practical Lipid Management: Concepts and Controversies

Practical Lipid Management: Concepts and Controversies

How to Cite

Toth, P. P. and Maki, K. C. (2008) Management of Elevated Triglycerides and Non-High-Density Lipoprotein Cholesterol , in Practical Lipid Management: Concepts and Controversies, John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470696873.ch6

Author Information

  1. 1

    Sterling Rock Falls Clinic, Ltd., USA

  2. 2

    CGH Medical Center Sterling, Illinois, USA

  3. 3

    Departments of Family and Community Medicine, University of Illinois College of Medicine Peoria, Illinois, USA

  4. 4

    Southern Illinois University School of Medicine, Springfield, Illinois, USA

  5. 5

    Provident Clinical Research & Consulting, Inc., Glen Ellyn, Illinois and Bloomington, Indiana, USA

Publication History

  1. Published Online: 1 OCT 2008
  2. Published Print: 17 OCT 2008

ISBN Information

Print ISBN: 9780470056905

Online ISBN: 9780470696873

SEARCH

Keywords:

  • elevated triglyceride management;
  • TG-rich lipoproteins and atherosclerosis and CHD;
  • TG-rich lipoprotein clearence impedance;
  • insulin resistance and hypertriglyceridemia;
  • lifestyle management;
  • VLDL-C lowering - fibrates, niacin, and omega-3 fatty acids;
  • diabetic dyslipidemia management;
  • fasting triglyceride level and low-density lipoprotein (LDL)

Summary

This chapter contains sections titled:

  • Clinical Factors Associated with Elevated TG and Non-HDL-C Levels

  • Disorders of TG-Rich Lipoprotein Clearance

  • Insulin Resistance and Hypertriglyceridemia

  • Excessive Production of VLDL: The Primary Lipid Abnormality in the Insulin-Resistant State

  • Reasons for Elevated Free Fatty Acid Levels in Insulin-Resistant States

  • Body Fat Distribution and Insulin Resistance

  • Insulin Resistance in the Nonobese Patient

  • Hypertriglyceridemia and the Development of Atherogenic Dyslipidemia

  • Lifestyle Management for the Metabolic Syndrome and Atherogenic Dyslipidemia

  • Drug Therapies

  • Intensification of Efforts to Lower LDL-C as a Means of Achieving the Non-HDL-C Goal

  • Targeting Triglyceride-Rich Lipoprotein Reduction as a Means of Achieving Non-HDL-C Goal

  • Fibrates

  • Niacin

  • Omega-3 Fatty Acids

  • Management of Diabetic Dyslipidemia

  • Controversy: Do we Need a Triglyceride Treatment Target to Insure a Predominance of Larger, More Buoyant LDL Particles?